查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2084962

血管性水腫治療市場：2026-2032年全球市場預測（依藥物類別、給藥途徑、疾病類型、最終用戶和分銷管道分類）

Angioedema Treatment Market by Drug Class, Administration Route, Disease Type, End User, Distribution Channel - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 186 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，血管性水腫治療市場將成長至 213.6 億美元，複合年成長率為 18.60%。

主要市場統計數據
基準年 2025 64.7億美元
預計年份：2026年 76.2億美元
預測年份 2032 213.6億美元
複合年成長率 (%) 18.60%

血管性水腫的治療正從被動的急救措施轉向針對組織胺介導、緩激肽介導、遺傳性、後天性和藥物誘發性疾病的標靶、機制性治療。這種治療需求的根本在於臨床上必須預防氣道阻塞，減少急診就診次數，並提高那些發作不可預測、疼痛劇烈且可能危及生命的患者的生活品質。

遺傳性血管性水腫的治療領域呈現最顯著的成長動能。 C1酯酶抑制劑替代療法、緩激肽B2受體拮抗劑、血漿激肽釋放酶抑制劑以及新型預防性生物製劑和口服療法，正在拓展傳統雄性激素療法以外的治療選擇。此外，人們對該疾病診斷的認知不斷提高、C4和C1-INH檢測的廣泛應用、轉診至專科醫生的途徑日益完善，以及患者對居家給藥和口服療法的偏好，也推動了市場需求的成長。

血管性水腫治療前景的變革性變化

精準醫療、快速診斷以及對組織胺介導的腫脹和緩激肽介導的疾病更清晰的區分，正在重新定義血管性水腫的治療。這種區分在商業性和臨床上都至關重要，因為過敏性血管性水腫通常需要使用抗組織胺、皮質類固醇，如果懷疑發生過敏反應，則需使用腎上腺素；而遺傳性血管性水腫和ACE抑制劑相關病例則需要針對緩激肽通路而非傳統過敏治療方案的治療策略。

人工智慧對血管性水腫治療的累積影響

人工智慧在血管性水腫的整個管理過程中累積創造價值，尤其是在早期識別罕見的遺傳性血管性水腫模式方面。人工智慧驅動的臨床決策支援有助於識別一些通常先於專科醫生診斷的徵兆，例如反覆發作的腹痛、無蕁麻疹的腫脹、家族病史、C4 水平降低或對抗組織胺反應不佳。

血管性水腫治療的關鍵區域見解

北美仍然是血管性水腫治療領域最成熟的地區，其中美國發揮主導作用。在美國，針對罕見疾病的完善保險報銷系統、廣泛的專科醫生網路和成熟的急救醫療方案已經建立，並且C1抑製劑、緩激肽拮抗劑、單克隆抗體和口服激肽釋放酶抑製劑等藥物也已得到早期應用。在加拿大，公共和私人保險的報銷審核流程也為這些藥物的穩定應用提供了支持，但不同省份、保險覆蓋範圍和治療環境可能會有所不同。

對血管性水腫市場主要經濟群的洞察

由於罕見疾病政策成熟、專家密度高、藥物安全監測體系完善，以及支付方對高價值生物製藥製劑和孤兒藥的高度商業性，七國集團（G7）市場為高品質血管性水腫治療藥物提供了最強大的商業基礎。在該集團中，美國、德國、日本、法國、義大利、英國和加拿大共同塑造全球製藥公司在臨床導入、定價預期、證據標準和真實世界療效要求方面的模式。

主要國家血管性水腫治療趨勢

美國憑藉其經FDA已通過核准的急性期和預防性治療方案、廣泛的過敏和免疫學專家網路、積極的患者支持活動以及完善的居家給藥途徑，在全球血管性水腫治療領域處於領先地位。加拿大緊隨其後，透過實證醫學的報銷審查和提高遺傳性血管性水腫標靶治療的可及性來應對這一挑戰。墨西哥和巴西是拉丁美洲最重要的市場，兩國擁有都市區專科醫療中心，能夠支持診斷和治療，但由於報銷問題、經濟負擔以及公共醫療覆蓋範圍的差異，更廣泛的醫療服務仍然受到限制。

為血管性水腫行業的領導者提供的實用建議

產業領導者應優先考慮差異化的臨床價值，特別是快速緩解癲癇發作、降低發作頻率、給藥方便、安全性高以及改善患者報告的療效。隨著患者和臨床醫生尋求負擔更輕的治療模式，能夠減少急診就診次數、支持患者自行給藥或提供口服給藥便利的產品將佔據有利地位。

調查方法

本執行摘要是基於對已驗證的二手資料的系統性回顧，這些資料包括法規核准文件、臨床指南、同行評審文獻、罕見疾病政策文件、衛生技術評估材料、二級資訊來源安全檢驗資源以及公開的流行病學和治療可及性證據。本分析著重於已通過核准的療法、已知的疾病機制和已建立的臨床路徑，而非推測性論點。

結論

血管性水腫治療市場正進入一個更成熟的階段，其特徵是標靶治療的出現、疾病分類的細化、預防措施的拓展以及對便捷的居家治療和口服治療日益成長的需求。隨著臨床意識的提高，預計越來越多的患者將從每次發作都接受急診治療，轉向基於疾病機制、發作頻率和患者意願的個人化長期管理。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 市場動態
  • 波特五力分析
  • PESTLE分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：人工智慧的累積影響，2026年

第7章 血管性水腫治療市場：依藥物類別分類

  • 緩激肽受體拮抗劑
  • C1抑制劑
  • 激肽釋放酶抑制劑

第8章 血管性水腫治療市場：依給藥途徑分類

  • 注射藥物
  • 口服

第9章 血管性水腫治療市場：依疾病類型分類

  • 獲得
  • 遺傳
  • 特發性

第10章 血管性水腫治療市場：依最終用戶分類

  • 居家照護
  • 醫院
  • 專科診所

第11章 血管性水腫治療市場：依通路分類

  • 醫院藥房
  • 網路藥房
  • 零售藥房

第12章 血管性水腫治療市場：依地區分類

  • 亞太地區
  • 北美洲
  • 拉丁美洲
  • 歐洲
  • 中東
  • 非洲

第13章 血管性水腫治療市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第14章 血管性水腫治療市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第15章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年

第16章：公司簡介

  • Adverum Biotechnologies, Inc.
  • Argenx NV
  • AstraZeneca plc
  • Attune Pharmaceuticals, Inc.
  • Aurobindo Pharma Ltd.
  • Bayer AG
  • BioCryst Pharmaceuticals, Inc.
  • Cipla Limited
  • CSL Behring
  • Dr. Reddy's Laboratories Ltd.
  • GlaxoSmithKline plc
  • HAE Pharma LLC
  • Intellia Therapeutics, Inc.
  • Ionis Pharmaceuticals, Inc.
  • KalVista Pharmaceuticals Ltd.
  • Merck & Co., Inc.
  • Novartis AG
  • Otsuka Pharmaceutical Co., Ltd.
  • Pfizer Inc.
  • Pharming Group NV
  • Pharvaris Netherlands BV
  • Sanofi SA
  • Sobi
  • Takeda Pharmaceutical Company Limited
  • Teva Pharmaceutical Industries Ltd.
Product Code: MRR-43690106621A

The Angioedema Treatment Market is projected to grow by USD 21.36 billion at a CAGR of 18.60% by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 6.47 billion
Estimated Year [2026] USD 7.62 billion
Forecast Year [2032] USD 21.36 billion
CAGR (%) 18.60%

Angioedema treatment is shifting from reactive emergency management to targeted, mechanism-based care for histaminergic, bradykinin-mediated, hereditary, acquired, and drug-induced disease. Treatment demand is anchored by the clinical need to prevent airway compromise, reduce emergency department utilization, and improve quality of life for patients whose attacks can be unpredictable, painful, and potentially life-threatening.

The strongest growth signals are concentrated in hereditary angioedema treatment, where C1 esterase inhibitor replacement, bradykinin B2 receptor antagonism, plasma kallikrein inhibition, and newer prophylactic biologics and oral therapies have expanded options beyond older androgen-based regimens. Demand is also supported by improved diagnostic awareness, wider availability of C4 and C1-INH testing, specialist referral pathways, and patient preference for home-administered or oral therapies.

Transformative Shifts in the Angioedema Treatment Landscape

The angioedema treatment landscape is being reshaped by precision medicine, faster diagnosis, and a clearer separation between histamine-mediated swelling and bradykinin-mediated disease. This distinction is commercially and clinically important because allergic angioedema typically relies on antihistamines, corticosteroids, and epinephrine when anaphylaxis is suspected, while hereditary angioedema and ACE inhibitor-associated cases require bradykinin-pathway strategies rather than conventional allergy protocols.

Transformative shifts include the rise of long-term prophylaxis, patient-administered rescue therapy, and oral treatment alternatives that reduce dependence on infusion-based care. Payers and providers are increasingly evaluating therapies through attack reduction, time to symptom relief, reduced hospitalization, adherence, safety, and total cost of care, creating opportunities for innovators that can demonstrate durable outcomes in real-world populations.

Cumulative Impact of Artificial Intelligence on Angioedema Care

Artificial intelligence is creating cumulative value across the angioedema care pathway, particularly in earlier recognition of rare hereditary angioedema patterns. AI-enabled clinical decision support can help flag recurrent abdominal pain, swelling without urticaria, family history, low C4 results, or poor response to antihistamines, which are signals that often precede specialist diagnosis.

In drug development and commercialization, AI is improving trial feasibility, patient identification, adverse-event monitoring, and real-world evidence generation. Natural language processing can support pharmacovigilance for biologics and oral kallikrein inhibitors, while predictive analytics can help health systems identify high-risk patients who may benefit from prophylaxis or structured home-treatment plans. These applications strengthen market access when paired with validated clinical oversight, privacy safeguards, and transparent data governance.

Key Regional Insights for Angioedema Treatment

North America remains the most mature angioedema treatment region, led by the United States with strong rare disease reimbursement infrastructure, broad specialist networks, established emergency-care protocols, and early adoption of C1-INH products, bradykinin antagonists, monoclonal antibodies, and oral kallikrein inhibitors. Canada shows steady uptake supported by public and private reimbursement review pathways, though access can vary by province, formulary status, and treatment setting.

Europe is characterized by established hereditary angioedema clinical guidelines, strong academic centers, and structured access across major markets including Germany, France, Italy, Spain, and the United Kingdom. The European Union's centralized regulatory framework supports cross-border evidence standards, while national health technology assessment bodies maintain pricing discipline and require robust outcomes evidence for acute therapy, prophylaxis, and long-term disease control.

Asia-Pacific is expanding as Japan, China, South Korea, Australia, and India improve rare disease recognition and specialist referral capacity. Japan and Australia have relatively advanced access environments, while China and India present long-term treatment potential as diagnostic availability, physician education, and reimbursement pathways develop. Latin America, led by Brazil and Mexico, is progressing through specialty-care adoption but continues to face uneven access, affordability barriers, and differences between public and private systems. The Middle East, particularly GCC countries, benefits from investment in tertiary care, government-funded specialty treatment, and imported innovative medicines, while Africa remains an underpenetrated region where diagnosis, product availability, affordability, and acute-care readiness remain central challenges.

Key Economic Group Insights Across Angioedema Markets

The G7 markets provide the strongest commercial foundation for premium angioedema therapies because of rare disease policy maturity, specialist density, established pharmacovigilance systems, and payer familiarity with high-value biologics and orphan medicines. Within this group, the United States, Germany, Japan, France, Italy, the United Kingdom, and Canada collectively shape clinical adoption patterns, pricing expectations, evidence standards, and real-world outcome requirements for global manufacturers.

The European Union is influential because centralized authorization can support market entry, while individual member states determine reimbursement, prescribing restrictions, budget impact management, and patient access timelines. NATO countries overlap significantly with high-income markets and maintain advanced emergency-care systems, which is important for acute angioedema management, airway-risk protocols, and hospital readiness.

BRICS markets represent long-term volume potential rather than uniform near-term access. China, India, and Brazil are particularly important because of large patient pools and improving rare disease policy frameworks, while Russia and South Africa face more variable availability and reimbursement dynamics. ASEAN markets are heterogeneous, with Singapore, Thailand, Malaysia, Indonesia, Vietnam, and the Philippines differing widely in diagnostic capacity, specialist concentration, and specialty drug funding. GCC countries show strong potential for advanced therapies because tertiary hospitals, government-funded care, genetic disease initiatives, and medical tourism strategies support rare disease treatment adoption.

Key Country Insights in Angioedema Treatment

The United States leads global angioedema treatment adoption due to FDA-approved acute and prophylactic options, extensive allergist-immunologist networks, strong patient advocacy activity, and established pathways for home administration. Canada follows with evidence-based reimbursement review and growing use of targeted hereditary angioedema therapies. Mexico and Brazil are the most important Latin American markets, where urban specialty centers support diagnosis and treatment but broader access remains constrained by reimbursement, affordability, and public-system coverage variation.

In Europe, the United Kingdom, Germany, France, Italy, and Spain benefit from established rare disease systems, clinical guidelines, and specialist-led care pathways. Germany's early access environment and physician autonomy support rapid adoption after approval, while France, Italy, and Spain emphasize negotiated reimbursement and guideline-supported use. The United Kingdom relies on health technology assessment and specialized commissioning to balance clinical value with budget impact. Russia has pockets of specialty access but faces greater variability in product availability, reimbursement consistency, and continuity of supply.

In Asia-Pacific, China and India offer the largest long-term patient opportunities as awareness, diagnostic capacity, and rare disease policy attention improve. Japan and South Korea have advanced healthcare systems and strong regulatory capabilities that support innovative therapies and specialist management. Australia provides a structured reimbursement environment and high clinical awareness in rare disease centers, making it an important regional benchmark for access, outcomes tracking, and patient-centered care.

Actionable Recommendations for Angioedema Industry Leaders

Industry leaders should prioritize differentiated clinical value, especially faster attack relief, lower attack frequency, easier administration, favorable safety, and improved patient-reported outcomes. Products that reduce emergency visits, support self-administration, or offer oral convenience are well positioned as patients and clinicians seek less burdensome treatment models.

Manufacturers should invest in diagnostic education for emergency physicians, allergists, immunologists, gastroenterologists, dermatologists, and primary care providers because delayed recognition remains a major barrier in hereditary and bradykinin-mediated angioedema. Market access teams should build evidence packages around real-world effectiveness, adherence, health economic impact, quality-of-life gains, and reduced acute-care utilization.

Commercial strategies should also be region-specific. Mature markets require strong payer dossiers and comparative value evidence, while emerging markets need physician education, patient identification, local partnerships, and tiered access models. Across all markets, patient support programs, home-treatment training, digital adherence tools, and registry-based evidence can strengthen persistence and outcomes.

Research Methodology

This executive summary is based on a structured review of verified secondary sources, including regulatory approvals, clinical guidelines, peer-reviewed literature, rare disease policy documents, health technology assessment materials, pharmacovigilance resources, and publicly available epidemiology and treatment-access evidence. The analysis emphasizes approved therapies, recognized mechanisms of disease, and established clinical pathways rather than speculative claims.

Market interpretation combines qualitative assessment of regulatory environments, reimbursement dynamics, clinical adoption, regional healthcare infrastructure, emergency-care capacity, and patient access barriers. Insights are triangulated across multiple source categories to support accuracy, consistency, and relevance for stakeholders in pharmaceutical strategy, market access, competitive intelligence, and healthcare investment.

Conclusion

The angioedema treatment market is entering a more advanced phase defined by targeted therapies, better disease classification, expanding prophylaxis, and increasing demand for convenient home-based and oral options. As clinical awareness improves, more patients are expected to move from episodic emergency care toward individualized long-term management based on disease mechanism, attack burden, and patient preference.

Future leadership will depend on evidence-backed differentiation, global access planning, patient-centered support, and credible real-world outcomes. Organizations that align innovation with affordability, earlier diagnosis, safe administration, and measurable clinical benefit will be best positioned to expand access across both mature rare disease markets and emerging healthcare systems.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Market Dynamics
    • 4.3.1. Key Drivers
    • 4.3.2. Key Restraints
    • 4.3.3. Key Opportunities
    • 4.3.4. Key Challenges
  • 4.4. Porter's Five Forces Analysis
  • 4.5. PESTLE Analysis
  • 4.6. Market Outlook
    • 4.6.1. Near-Term Market Outlook (0-2 Years)
    • 4.6.2. Medium-Term Market Outlook (3-5 Years)
    • 4.6.3. Long-Term Market Outlook (5-10 Years)
  • 4.7. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Angioedema Treatment Market, by Drug Class

  • 7.1. Bradykinin Receptor Antagonists
  • 7.2. C1 Inhibitors
  • 7.3. Kallikrein Inhibitors

8. Angioedema Treatment Market, by Administration Route

  • 8.1. Injectable
  • 8.2. Oral

9. Angioedema Treatment Market, by Disease Type

  • 9.1. Acquired
  • 9.2. Hereditary
  • 9.3. Idiopathic

10. Angioedema Treatment Market, by End User

  • 10.1. Home Care
  • 10.2. Hospitals
  • 10.3. Specialty Clinics

11. Angioedema Treatment Market, by Distribution Channel

  • 11.1. Hospital Pharmacy
  • 11.2. Online Pharmacy
  • 11.3. Retail Pharmacy

12. Angioedema Treatment Market, by Region

  • 12.1. Asia-Pacific
  • 12.2. North America
  • 12.3. Latin America
  • 12.4. Europe
  • 12.5. Middle East
  • 12.6. Africa

13. Angioedema Treatment Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Angioedema Treatment Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. Competitive Landscape

  • 15.1. Market Concentration Analysis, 2025
    • 15.1.1. Concentration Ratio (CR)
    • 15.1.2. Herfindahl Hirschman Index (HHI)
  • 15.2. Recent Developments & Impact Analysis, 2025
  • 15.3. Product Portfolio Analysis, 2025
  • 15.4. Benchmarking Analysis, 2025

16. Company Profiles

  • 16.1. Adverum Biotechnologies, Inc.
  • 16.2. Argenx NV
  • 16.3. AstraZeneca plc
  • 16.4. Attune Pharmaceuticals, Inc.
  • 16.5. Aurobindo Pharma Ltd.
  • 16.6. Bayer AG
  • 16.7. BioCryst Pharmaceuticals, Inc.
  • 16.8. Cipla Limited
  • 16.9. CSL Behring
  • 16.10. Dr. Reddy's Laboratories Ltd.
  • 16.11. GlaxoSmithKline plc
  • 16.12. HAE Pharma LLC
  • 16.13. Intellia Therapeutics, Inc.
  • 16.14. Ionis Pharmaceuticals, Inc.
  • 16.15. KalVista Pharmaceuticals Ltd.
  • 16.16. Merck & Co., Inc.
  • 16.17. Novartis AG
  • 16.18. Otsuka Pharmaceutical Co., Ltd.
  • 16.19. Pfizer Inc.
  • 16.20. Pharming Group N.V.
  • 16.21. Pharvaris Netherlands B.V.
  • 16.22. Sanofi S.A.
  • 16.23. Sobi
  • 16.24. Takeda Pharmaceutical Company Limited
  • 16.25. Teva Pharmaceutical Industries Ltd.

LIST OF FIGURES

  • FIGURE 1. GLOBAL ANGIOEDEMA TREATMENT MARKET, YEARS CONSIDERED FOR THE STUDY
  • FIGURE 2. GLOBAL ANGIOEDEMA TREATMENT MARKET, RESEARCH DESIGN
  • FIGURE 3. GLOBAL ANGIOEDEMA TREATMENT MARKET, RESEARCH FRAMEWORK
  • FIGURE 4. GLOBAL ANGIOEDEMA TREATMENT MARKET, DATA TRIANGULATION
  • FIGURE 5. GLOBAL ANGIOEDEMA TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 6. GLOBAL ANGIOEDEMA TREATMENT MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 7. GLOBAL ANGIOEDEMA TREATMENT MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 8. GLOBAL ANGIOEDEMA TREATMENT MARKET SIZE, BY DRUG CLASS, 2025 VS 2032 (%)
  • FIGURE 9. GLOBAL ANGIOEDEMA TREATMENT MARKET SIZE, BY DRUG CLASS, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL ANGIOEDEMA TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2025 VS 2032 (%)
  • FIGURE 11. GLOBAL ANGIOEDEMA TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL ANGIOEDEMA TREATMENT MARKET SIZE, BY DISEASE TYPE, 2025 VS 2032 (%)
  • FIGURE 13. GLOBAL ANGIOEDEMA TREATMENT MARKET SIZE, BY DISEASE TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 14. GLOBAL ANGIOEDEMA TREATMENT MARKET SIZE, BY END USER, 2025 VS 2032 (%)
  • FIGURE 15. GLOBAL ANGIOEDEMA TREATMENT MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 16. GLOBAL ANGIOEDEMA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2032 (%)
  • FIGURE 17. GLOBAL ANGIOEDEMA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 18. GLOBAL ANGIOEDEMA TREATMENT MARKET SIZE, BY REGION, 2025 VS 2032 (%)
  • FIGURE 19. GLOBAL ANGIOEDEMA TREATMENT MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 20. GLOBAL ANGIOEDEMA TREATMENT MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
  • FIGURE 21. GLOBAL ANGIOEDEMA TREATMENT MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 22. GLOBAL ANGIOEDEMA TREATMENT MARKET SIZE, BY COUNTRY, 2025 VS 2032 (%)
  • FIGURE 23. GLOBAL ANGIOEDEMA TREATMENT MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL ANGIOEDEMA TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL ANGIOEDEMA TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL BRADYKININ RECEPTOR ANTAGONISTS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL BRADYKININ RECEPTOR ANTAGONISTS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL BRADYKININ RECEPTOR ANTAGONISTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL C1 INHIBITORS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL C1 INHIBITORS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL C1 INHIBITORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL KALLIKREIN INHIBITORS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL KALLIKREIN INHIBITORS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL KALLIKREIN INHIBITORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL ANGIOEDEMA TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL INJECTABLE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL INJECTABLE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL INJECTABLE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL ORAL MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL ORAL MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL ORAL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL ANGIOEDEMA TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL ACQUIRED MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL ACQUIRED MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL ACQUIRED MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL HEREDITARY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL HEREDITARY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL HEREDITARY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL IDIOPATHIC MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL IDIOPATHIC MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL IDIOPATHIC MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL ANGIOEDEMA TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL HOME CARE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL HOME CARE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL HOME CARE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL HOSPITALS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL HOSPITALS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL HOSPITALS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL SPECIALTY CLINICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL SPECIALTY CLINICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL SPECIALTY CLINICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL ANGIOEDEMA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL HOSPITAL PHARMACY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL HOSPITAL PHARMACY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL HOSPITAL PHARMACY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL ONLINE PHARMACY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL ONLINE PHARMACY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL ONLINE PHARMACY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL RETAIL PHARMACY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL RETAIL PHARMACY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL RETAIL PHARMACY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL ANGIOEDEMA TREATMENT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 50. ASIA-PACIFIC ANGIOEDEMA TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 51. ASIA-PACIFIC ANGIOEDEMA TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 52. ASIA-PACIFIC ANGIOEDEMA TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 53. ASIA-PACIFIC ANGIOEDEMA TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 54. ASIA-PACIFIC ANGIOEDEMA TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 55. ASIA-PACIFIC ANGIOEDEMA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 56. NORTH AMERICA ANGIOEDEMA TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 57. NORTH AMERICA ANGIOEDEMA TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 58. NORTH AMERICA ANGIOEDEMA TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 59. NORTH AMERICA ANGIOEDEMA TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 60. NORTH AMERICA ANGIOEDEMA TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 61. NORTH AMERICA ANGIOEDEMA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 62. LATIN AMERICA ANGIOEDEMA TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 63. LATIN AMERICA ANGIOEDEMA TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 64. LATIN AMERICA ANGIOEDEMA TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 65. LATIN AMERICA ANGIOEDEMA TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 66. LATIN AMERICA ANGIOEDEMA TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 67. LATIN AMERICA ANGIOEDEMA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 68. EUROPE ANGIOEDEMA TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 69. EUROPE ANGIOEDEMA TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 70. EUROPE ANGIOEDEMA TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 71. EUROPE ANGIOEDEMA TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 72. EUROPE ANGIOEDEMA TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 73. EUROPE ANGIOEDEMA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 74. MIDDLE EAST ANGIOEDEMA TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 75. MIDDLE EAST ANGIOEDEMA TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 76. MIDDLE EAST ANGIOEDEMA TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 77. MIDDLE EAST ANGIOEDEMA TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 78. MIDDLE EAST ANGIOEDEMA TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 79. MIDDLE EAST ANGIOEDEMA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 80. AFRICA ANGIOEDEMA TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 81. AFRICA ANGIOEDEMA TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 82. AFRICA ANGIOEDEMA TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 83. AFRICA ANGIOEDEMA TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 84. AFRICA ANGIOEDEMA TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 85. AFRICA ANGIOEDEMA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL ANGIOEDEMA TREATMENT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 87. ASEAN ANGIOEDEMA TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 88. ASEAN ANGIOEDEMA TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 89. ASEAN ANGIOEDEMA TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 90. ASEAN ANGIOEDEMA TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 91. ASEAN ANGIOEDEMA TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 92. ASEAN ANGIOEDEMA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 93. GCC ANGIOEDEMA TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 94. GCC ANGIOEDEMA TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 95. GCC ANGIOEDEMA TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 96. GCC ANGIOEDEMA TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 97. GCC ANGIOEDEMA TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 98. GCC ANGIOEDEMA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 99. EUROPEAN UNION ANGIOEDEMA TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 100. EUROPEAN UNION ANGIOEDEMA TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 101. EUROPEAN UNION ANGIOEDEMA TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 102. EUROPEAN UNION ANGIOEDEMA TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 103. EUROPEAN UNION ANGIOEDEMA TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 104. EUROPEAN UNION ANGIOEDEMA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 105. BRICS ANGIOEDEMA TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 106. BRICS ANGIOEDEMA TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 107. BRICS ANGIOEDEMA TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 108. BRICS ANGIOEDEMA TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 109. BRICS ANGIOEDEMA TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 110. BRICS ANGIOEDEMA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 111. G7 ANGIOEDEMA TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 112. G7 ANGIOEDEMA TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 113. G7 ANGIOEDEMA TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 114. G7 ANGIOEDEMA TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 115. G7 ANGIOEDEMA TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 116. G7 ANGIOEDEMA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 117. NATO ANGIOEDEMA TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 118. NATO ANGIOEDEMA TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 119. NATO ANGIOEDEMA TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 120. NATO ANGIOEDEMA TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 121. NATO ANGIOEDEMA TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 122. NATO ANGIOEDEMA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 123. GLOBAL ANGIOEDEMA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 124. UNITED STATES ANGIOEDEMA TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 125. UNITED STATES ANGIOEDEMA TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 126. UNITED STATES ANGIOEDEMA TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 127. UNITED STATES ANGIOEDEMA TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 128. UNITED STATES ANGIOEDEMA TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 129. UNITED STATES ANGIOEDEMA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 130. CANADA ANGIOEDEMA TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 131. CANADA ANGIOEDEMA TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 132. CANADA ANGIOEDEMA TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 133. CANADA ANGIOEDEMA TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 134. CANADA ANGIOEDEMA TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 135. CANADA ANGIOEDEMA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 136. MEXICO ANGIOEDEMA TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 137. MEXICO ANGIOEDEMA TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 138. MEXICO ANGIOEDEMA TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 139. MEXICO ANGIOEDEMA TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 140. MEXICO ANGIOEDEMA TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 141. MEXICO ANGIOEDEMA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 142. BRAZIL ANGIOEDEMA TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 143. BRAZIL ANGIOEDEMA TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 144. BRAZIL ANGIOEDEMA TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 145. BRAZIL ANGIOEDEMA TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 146. BRAZIL ANGIOEDEMA TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 147. BRAZIL ANGIOEDEMA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 148. UNITED KINGDOM ANGIOEDEMA TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 149. UNITED KINGDOM ANGIOEDEMA TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 150. UNITED KINGDOM ANGIOEDEMA TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 151. UNITED KINGDOM ANGIOEDEMA TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 152. UNITED KINGDOM ANGIOEDEMA TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 153. UNITED KINGDOM ANGIOEDEMA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 154. GERMANY ANGIOEDEMA TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 155. GERMANY ANGIOEDEMA TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 156. GERMANY ANGIOEDEMA TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 157. GERMANY ANGIOEDEMA TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 158. GERMANY ANGIOEDEMA TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 159. GERMANY ANGIOEDEMA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 160. FRANCE ANGIOEDEMA TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 161. FRANCE ANGIOEDEMA TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 162. FRANCE ANGIOEDEMA TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 163. FRANCE ANGIOEDEMA TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 164. FRANCE ANGIOEDEMA TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 165. FRANCE ANGIOEDEMA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 166. RUSSIA ANGIOEDEMA TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 167. RUSSIA ANGIOEDEMA TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 168. RUSSIA ANGIOEDEMA TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 169. RUSSIA ANGIOEDEMA TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 170. RUSSIA ANGIOEDEMA TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 171. RUSSIA ANGIOEDEMA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 172. ITALY ANGIOEDEMA TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 173. ITALY ANGIOEDEMA TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 174. ITALY ANGIOEDEMA TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 175. ITALY ANGIOEDEMA TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 176. ITALY ANGIOEDEMA TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 177. ITALY ANGIOEDEMA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 178. SPAIN ANGIOEDEMA TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 179. SPAIN ANGIOEDEMA TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 180. SPAIN ANGIOEDEMA TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 181. SPAIN ANGIOEDEMA TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 182. SPAIN ANGIOEDEMA TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 183. SPAIN ANGIOEDEMA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 184. CHINA ANGIOEDEMA TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 185. CHINA ANGIOEDEMA TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 186. CHINA ANGIOEDEMA TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 187. CHINA ANGIOEDEMA TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 188. CHINA ANGIOEDEMA TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 189. CHINA ANGIOEDEMA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 190. INDIA ANGIOEDEMA TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 191. INDIA ANGIOEDEMA TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 192. INDIA ANGIOEDEMA TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 193. INDIA ANGIOEDEMA TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 194. INDIA ANGIOEDEMA TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 195. INDIA ANGIOEDEMA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 196. JAPAN ANGIOEDEMA TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 197. JAPAN ANGIOEDEMA TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 198. JAPAN ANGIOEDEMA TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 199. JAPAN ANGIOEDEMA TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 200. JAPAN ANGIOEDEMA TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 201. JAPAN ANGIOEDEMA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 202. AUSTRALIA ANGIOEDEMA TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 203. AUSTRALIA ANGIOEDEMA TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 204. AUSTRALIA ANGIOEDEMA TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 205. AUSTRALIA ANGIOEDEMA TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 206. AUSTRALIA ANGIOEDEMA TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 207. AUSTRALIA ANGIOEDEMA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 208. SOUTH KOREA ANGIOEDEMA TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 209. SOUTH KOREA ANGIOEDEMA TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 210. SOUTH KOREA ANGIOEDEMA TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 211. SOUTH KOREA ANGIOEDEMA TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 212. SOUTH KOREA ANGIOEDEMA TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 213. SOUTH KOREA ANGIOEDEMA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)